Advanced degree (PhD, PharmD, or equivalent) in health economics, epidemiology, public health, economics, or related field; or Master's degree with 4-5+ years of relevant HEOR experience.
Completion of a relevant fellowship or 2+ years of experience in health economics or outcomes research.
Foundational knowledge in health economic modeling and real-world evidence generation.
Understanding of global health technology assessment processes and payer decision-making frameworks.
Familiarity with AI and digital tools relevant to health economics, including data analytics platforms.
Responsibilities
Lead US-focused HEOR activities for AYVAKIT® in Systemic Mastocytosis and emerging assets.
Translate HEVA evidence into US business and policy impact through payer engagement and access strategies.
Design research programs to meet evidentiary standards for US reimbursement authorities and third-party payers.
Represent US HEVA within the global HEVA team, ensuring US perspectives are included in global strategies.
Collaborate with Medical Affairs and Policy teams to ensure effective use of HEOR evidence in communications and training.
Mentor junior colleagues on US HEOR and market access expertise.
Benefits
Participation in company employee benefit programs.
Opportunities for professional development and training.
Collaborative work environment with cross-functional teams.
This role will lead US-focused Health Economic and Outcomes Research activities for AYVAKIT® in Systemic Mastocytosis and emerging pipeline assets within the US Rare/Oncology HEVA team, providing US insights and executional leadership while remaining aligned to - but not accountable for - global HEVA strategy.
Lead the design and execution of US-focused HEOR for AYVAKIT® (avapritinib) in Systemic Mastocytosis and assigned emerging assets - including economic modelling, database analysis, observational research, RWE studies, systematic literature review, evidence synthesis, and AMCP dossier development - setting US evidence generation priorities and incorporating them into broader Sanofi planning documents such as the Integrated Evidence Generation Plan (IEGP); operate with medium independence for strategic work and high independence for tactical execution, consistent with L3-2 expectations.
Translate HEVA evidence into US business and policy impact by driving payer engagement, value positioning, and access strategies for AYVAKIT® in the US marketplace; understand and address US payer evidence requirements across managed care, specialty pharmacy, and rare disease payer dynamics; and support the development of compliant and impactful US evidence dissemination pathways (e.g., HCEI, PIE, CFL) including payer dossiers, field materials, and publications.
Operate as part of a multi-functional US brand team responsible for designing research programs to meet the evidentiary standards of US reimbursement authorities and third-party payers; provide recommendations to ensure clinical and real-world evidence programs support US payer differentiation and value demonstration; and contribute to cross-functional US planning processes including brand planning, lifecycle management, and launch readiness for AYVAKIT® and pipeline assets.
Serve as the US HEVA representative within the broader global HEVA team, ensuring the US perspective is well represented in global IEGPs, clinical development programs, and market access strategies; translate global evidence packages into US-specific value narratives and payer-facing materials; and engage with ICER review processes and the US policy landscape as relevant to Systemic Mastocytosis and emerging assets.
Partner with US Medical Affairs, Value & Access, and Policy teams to ensure appropriate use of HEOR evidence in field communications, payer engagement, and training; collaborate on evidence that informs value frameworks, PDAB and ICER responses, and value-based contracting strategies; and mentor junior colleagues on a case-by-case basis, sharing US HEOR and market access expertise.
About You
Basic Qualifications
Education:
Advanced degree (PhD, PharmD, or equivalent) in health economics, epidemiology, public health, economics, or a related field; or Master's degree in a related field + minimum 4-5+ years of relevant HEOR/outcomes research experience
Experience:
Completion of a relevant fellowship or minimum of 2+ years of experience in health economics, outcomes research, or a related field
Technical Skills:
Foundational knowledge in health economic modeling, real-world evidence generation, evidence synthesis, and outcomes research methodologies.
Understanding of global health technology assessment processes and payer decision-making frameworks.
Foundational knowledge of AI and digital tools relevant to health economics, including familiarity with data analytics platforms and digital research tools; demonstrated willingness to rapidly develop proficiency with new digital and AI-enabled solutions.
Soft Skills:
Strong written and verbal communication skills with ability to present technical information clearly to diverse audiences
Good project management skills with ability to manage timelines and deliverables while staying on budget
Entrepreneurial spirit, team orientation, and ability to develop creative solutions to complex problems
The salary range for this position is: $148,500.00 - $214,500.00
All compensation will be determined commensurate with demonstrated experience. Employees may be eligible to participate in Company employee benefit programs, and additional benefits information can be found here.
About Sanofi
Sanofi is a global pharmaceutical company that specializes in the research, development, and manufacturing of prescription drugs and vaccines. The company operates in over 170 countries and has a diverse portfolio of products that includes treatments for diabetes, cancer, cardiovascular disease, and rare diseases. Sanofi is committed to improving global health and has a strong focus on innovation and sustainability. The company has received numerous awards for its research and development efforts and is recognized as a leader in the pharmaceutical industry.
